NasdaqCM:NEOHealthcare
NeoGenomics (NEO) Stock Could Be 30.3% Undervalued on Its PanTracer Growth Narrative
NeoGenomics (NEO) is back on investor radars after recent trading showed sharp short term swings, with the stock down over the past week but up strongly over the past month and past 3 months.
See our latest analysis for NeoGenomics.
Looking past the latest pullback, NeoGenomics has a 1 year total shareholder return of 50.07% despite a year to date share price decline of 10.80%. This suggests recent momentum has cooled after a strong rebound over the past quarter.
If the recent swings in...